Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1994 Oct 1;309(6958):833–837. doi: 10.1136/bmj.309.6958.833

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.

T Hannedouche 1, P Landais 1, B Goldfarb 1, N el Esper 1, A Fournier 1, M Godin 1, D Durand 1, J Chanard 1, F Mignon 1, J M Suo 1, et al.
PMCID: PMC2541105  PMID: 7950612

Abstract

OBJECTIVE--To compare the ability of angiotensin converting enzyme inhibitors and beta blockers to slow the development of end stage renal failure in non-diabetic patients with chronic renal failure. DESIGN--Open randomised multicentre trial with three year follow up. SETTING--Outpatient departments of six French hospitals. PATIENTS--100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l. 52 randomised to enalapril and 48 to beta blockers (conventional treatment). INTERVENTIONS--Enalapril or beta blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg. RESULTS--17 patients receiving conventional treatment and 10 receiving enalapril developed end stage renal failure. The cumulative renal survival rate was significantly better in the enalapril group than in the conventional group (P < 0.05). The slope of the reciprocal serum creatinine concentration was steeper in the conventionally treated patients (-6.89 x 10(-5)l/mumol/month) than in the enalapril group (-4.17 x 10(-5)l/mumol/month; P < 0.05). No difference in blood pressure was found between groups. CONCLUSION--In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with beta blockers. This effect was probably not mediated through controlling blood pressure.

Full text

PDF
833

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvestrand A., Gutierrez A., Bucht H., Bergström J. Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant. 1988;3(5):624–631. doi: 10.1093/oxfordjournals.ndt.a091717. [DOI] [PubMed] [Google Scholar]
  2. Anderson S., Rennke H. G., Brenner B. M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986 Jun;77(6):1993–2000. doi: 10.1172/JCI112528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Björck S., Mulec H., Johnsen S. A., Nordén G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992 Feb 8;304(6823):339–343. doi: 10.1136/bmj.304.6823.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brazy P. C., Fitzwilliam J. F. Progressive renal disease: role of race and antihypertensive medications. Kidney Int. 1990 Apr;37(4):1113–1119. doi: 10.1038/ki.1990.93. [DOI] [PubMed] [Google Scholar]
  5. Brazy P. C., Stead W. W., Fitzwilliam J. F. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989 Feb;35(2):670–674. doi: 10.1038/ki.1989.37. [DOI] [PubMed] [Google Scholar]
  6. Cameron J. S. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 1990;10 (Suppl 1):81–87. doi: 10.1159/000168199. [DOI] [PubMed] [Google Scholar]
  7. DAVIES D. F., SHOCK N. W. The variability of measurement of insulin and diodrast tests of kidney function. J Clin Invest. 1950 May;29(5):491–495. doi: 10.1172/JCI102285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fenoy F. J., Scicli G., Carretero O., Roman R. J. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension. 1991 Jun;17(6 Pt 2):1038–1044. doi: 10.1161/01.hyp.17.6.1038. [DOI] [PubMed] [Google Scholar]
  9. Hannedouche T., Albouze G., Chauveau P., Lacour B., Jungers P. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure. Am J Kidney Dis. 1993 May;21(5 Suppl 2):131–137. doi: 10.1016/0272-6386(93)70104-7. [DOI] [PubMed] [Google Scholar]
  10. Hannedouche T., Laude D., Déchaux M., Grünfeld J. P., Elghozi J. L. Plasma 5-hydroxyindoleacetic acid as an endogenous index of renal plasma flow. Kidney Int. 1989 Jan;35(1):95–98. doi: 10.1038/ki.1989.13. [DOI] [PubMed] [Google Scholar]
  11. Heeg J. E., de Jong P. E., van der Hem G. K., de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989 Aug;36(2):272–279. doi: 10.1038/ki.1989.190. [DOI] [PubMed] [Google Scholar]
  12. Heeg J. E., de Jong P. E., van der Hem G. K., de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int. 1987 Jul;32(1):78–83. doi: 10.1038/ki.1987.174. [DOI] [PubMed] [Google Scholar]
  13. Hostetter T. H., Olson J. L., Rennke H. G., Venkatachalam M. A., Brenner B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981 Jul;241(1):F85–F93. doi: 10.1152/ajprenal.1981.241.1.F85. [DOI] [PubMed] [Google Scholar]
  14. Kamper A. L., Strandgaard S., Leyssac P. P. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992 Jul;5(7):423–430. doi: 10.1093/ajh/5.7.423. [DOI] [PubMed] [Google Scholar]
  15. Levey A. S., Perrone R. D., Madias N. E. Serum creatinine and renal function. Annu Rev Med. 1988;39:465–490. doi: 10.1146/annurev.me.39.020188.002341. [DOI] [PubMed] [Google Scholar]
  16. Mann J. F., Reisch C., Ritz E. Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study. Nephron. 1990;55 (Suppl 1):38–42. doi: 10.1159/000186033. [DOI] [PubMed] [Google Scholar]
  17. Maroni B. J., Steinman T. I., Mitch W. E. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985 Jan;27(1):58–65. doi: 10.1038/ki.1985.10. [DOI] [PubMed] [Google Scholar]
  18. Meyer T. W., Anderson S., Rennke H. G., Brenner B. M. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987 Mar;31(3):752–759. doi: 10.1038/ki.1987.62. [DOI] [PubMed] [Google Scholar]
  19. Moorhead J. F., Chan M. K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982 Dec 11;2(8311):1309–1311. doi: 10.1016/s0140-6736(82)91513-6. [DOI] [PubMed] [Google Scholar]
  20. Norman J. T. The role of angiotensin II in renal growth. Ren Physiol Biochem. 1991 Jul-Oct;14(4-5):175–185. doi: 10.1159/000173403. [DOI] [PubMed] [Google Scholar]
  21. Parving H. H., Hommel E., Smidt U. M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ. 1988 Oct 29;297(6656):1086–1091. doi: 10.1136/bmj.297.6656.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rosenberg M. E., Chmielewski D., Hostetter T. H. Effect of dietary protein on rat renin and angiotensinogen gene expression. J Clin Invest. 1990 Apr;85(4):1144–1149. doi: 10.1172/JCI114546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ruilope L. M., Miranda B., Morales J. M., Rodicio J. L., Romero J. C., Raij L. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis. 1989 Feb;13(2):120–126. doi: 10.1016/s0272-6386(89)80129-5. [DOI] [PubMed] [Google Scholar]
  24. Yoshida Y., Fogo A., Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989 Feb;35(2):654–660. doi: 10.1038/ki.1989.35. [DOI] [PubMed] [Google Scholar]
  25. Yoshida Y., Kawamura T., Ikoma M., Fogo A., Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989 Oct;36(4):626–635. doi: 10.1038/ki.1989.239. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES